
SS-31
Mitochondria-targeting peptide studied for cell energy and protection from oxidative stress.
For Research Use Only
Sold strictly for laboratory research. Not for human or veterinary use, ingestion, or clinical/diagnostic application.
The lower price is applied automatically once your cart holds 5 or more of this vial.
Bacteriostatic water included
About this peptide
SS-31 is a targeted four-amino-acid peptide engineered to cross directly into the cell’s powerhouse—the mitochondria. It selectively binds to cardiolipin, an essential lipid that maintains the inner mitochondrial membrane. Research indicates this binding action helps repair disrupted mitochondrial structure, restores natural cellular energy (ATP) production, and neutralizes oxidative stress directly at the source.
Why researchers reach for SS-31
Cardiolipin binding
Selectively concentrates at the inner mitochondrial membrane.
ROS reduction
Lowers reactive oxygen species in mitochondrial assays.
ATP output
Restores ATP synthesis in aged / diseased mitochondria models.
Key features
- ≥99% HPLC purity
- Cardiolipin-targeted tetrapeptide
- Mass-spec verified
- Cold-chain dispatch
How it works
Membrane stabilization
Preserves cristae curvature and supercomplex integrity.
Electron transport support
Improves Complex I/IV coupling in preclinical work.
Peroxidase-like activity
Neutralizes cardiolipin peroxidation intermediates.
Research dosage guidelines
Reference ranges only — reproduced from published preclinical literature. Not a recommendation for human use.
| Range | Reported dose | Note |
|---|---|---|
| Reported research range | 1–10 mg/day, once daily | Reference only |
| Higher research range | Up to 40 mg/day, once daily | Reference only |
| Typical reconstitution | 2 mL bacteriostatic water | Yields 5 mg/mL (5000 mcg/mL) |
Tracking this compound? Registered researchers can log active SS-31 protocols in their private Research Log.
Timing in research protocols
Once daily, continuous — no time-of-day requirement documented.
- The TAZPOWER programme used 40 mg subcutaneously once daily, in 12-week crossover arms with a 4-week washout, followed by an open-label extension out to 168 weeks.
- The FDA integrated review records the same once-daily regimen.
- No specific clock time or meal relationship is specified in the trial documentation.
- Endpoints improved progressively over months, so the studied pattern is long-term maintenance rather than a short cycle.
Drawn from published research protocols and pharmacology literature. Reference information for laboratory research only — not an instruction or guidance for use.
Technical specifications
- Sequence
- D-Arg-2,6-dimethylTyr-Lys-Phe-NH2
- Molecular weight
- 639.8 g/mol
- Purity
- ≥99% (HPLC)
- Form
- Lyophilized powder
- Vial size
- 10 mg
- Storage (lyophilised vial)
- Cool, dry and protected from light
- Storage (after reconstitution)
- 2–8°C
Published research
Peer-reviewed literature on SS-31. Links open in a new tab.
Research use notice
Sold for in vitro laboratory research only. Not for human or veterinary use, diagnosis, or therapy.
